Sciensano, Brussels, Belgium; University of Hasselt, Hasselt, Belgium.
Statens Serum Institut, Copenhagen, Denmark.
Vaccine. 2020 Apr 3;38(16):3243-3254. doi: 10.1016/j.vaccine.2020.02.082. Epub 2020 Mar 12.
The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies.
A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990-2000 and influenza-vaccine for birth years 1920-1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server.
The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997-2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain).
We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates.
在欧洲，加速疫苗的利益-风险合作（ADVANCE）是一个公私合作项目，旨在利用欧洲现有的医疗保健数据库开发和测试一种快速监测疫苗的利益-风险的系统。我们从电子医疗保健数据库中估计疫苗接种率，作为疫苗利益-风险研究的适宜性评估的一部分。
通过分布式网络方法进行了一项回顾性动态队列研究。使用时期流行率和逆概率加权方法，估计了 2006 年出生的麻疹疫苗、1990-2000 年出生的人乳头瘤病毒（HPV）疫苗和 1920-1950 年出生的流感疫苗的覆盖率。四个国家的七个数据库参与了研究：意大利（Pedianet、Val Padana）、西班牙（BIFAP、SIDIAP）、英国（RCGP-RSC、THIN）和丹麦（SSI/AUH）。数据库访问提供商提取数据，将其转换为通用结构，并在本地运行 R 脚本。创建的输出表在中央服务器上共享和汇总。
麻疹疫苗的总研究人群包括 274616 人，HPV 疫苗为 2011666 人，流感疫苗为 14904033 人。麻疹疫苗第一剂的覆盖率从 84.3%（丹麦）到 96.5%（意大利，Val Padana）不等，第二剂的覆盖率从 82.8%（意大利，Val Padana）到 90.9%（英国）不等，年龄均为 7 岁。汇总 1997-2000 年出生年份的 HPV 疫苗覆盖率，从 15 岁时的 60%（英国）到 88.3%（丹麦）不等。在丹麦，2009 年至 2015 年期间，65 岁及以上人群的流感疫苗覆盖率约为 43%，而在英国，该比例约为 68%，而在西班牙的加泰罗尼亚，该比例从 58%下降至 50%。
我们通过一个共同的程序获得了详细的、按年龄划分的覆盖率估计值。我们讨论了数据库之间的可比性和与已发表的国家估计值的可比性。
